A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste

Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
doi: https://doi.org/10.1101/2022.01.28.22270035
Back to top
Posted January 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
medRxiv 2022.01.28.22270035; doi: https://doi.org/10.1101/2022.01.28.22270035
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area